Boston Scientific Other, net decreased by 66.7% to $3.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 130.0%, from -$10.00M to $3.00M. Over 2 years (FY 2023 to FY 2025), Other, net shows an upward trend with a -69.8% CAGR.
Fluctuations are often non-recurring; significant changes should be analyzed via footnotes to determine if they represent structural shifts in financing strategy.
This metric aggregates miscellaneous cash flows related to financing activities that do not fall into primary categories...
Standard line item in cash flow statements; varies significantly by company based on the complexity of their capital structure.
financing_proceeds_from_payments_for_other_financing_activities| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$19.25M | -$19.25M | -$19.25M | -$19.25M | -$250.00K | -$250.00K | -$250.00K | -$250.00K | -$10.00M | $9.00M | -$1.00M | $9.00M | $3.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +98.7% | +0.0% | +0.0% | +0.0% | <-999% | +190.0% | -111.1% | >999% | -66.7% |
| YoY Change | — | — | — | — | +98.7% | +98.7% | +98.7% | +98.7% | <-999% | >999% | -300.0% | >999% | +130.0% |